Hipertermia cu efect anticancer

Terapia anticancer integrativa

Terapii anticancer

1. Hipertermia si brahiterapia cu beneficiu de supravietuire la glioblastoma multiforma, sudiu randomizat dublu orb placebo controlat

Hipertermia cu beneficiu de supravietuire Termoterapie
Hipertermia cu beneficiu de supravietuire Termoterapie

Terapii anticancer: Terapia biologica cu produse naturale

Terapii anticancer: Terapia biologica cu produse naturale

Terapia anticancer integrativa cu: Nutraceutice EGCG, L-Arginina, Vitamina D3 1000 U.I in formula ANTI-CANCER, Germaniu Organic in formula ANTICANCER-ONCOXIN, Echilibru Hormonal, Indole-3-Carbinol, Resveratrol, Ggheara Matei, Garlic, etc.

Terapia anticancer integrativa

Nutrienti anticancer: Vitamina C, L-Lizina, EGCG, N-Acetilcisteina

Nutrienti anticancer

L-Lizina blocheaza procesul de colagenaza
L-Lizina blocheaza procesul de colagenaza

Experiment de laborator cu celule de cancer
Experiment de laborator cu celule de cancer

A. Celule de cancer incubate in mediu de crestere fara: Vitamina C, L-Lizina, EGCG

B. Celule de cancer incubate in mediu de crestere cu: Vitamina C, L-Lizina, EGCG

Celule de cancer nu au posibilitatea sa treaca (colagenaza) prin matrixul de colagen (Matrigel)

AntiCancer Resveratrol Sinergie din:Farmacia Nasturala

AntiCancer Resveratrol Sinergie


Recomandare: Resveratrol Sinergie din Farmacia Nasturala este o formula avansata AntiCancer cu fito farmaceutice ca adjuvant in terapia cancerului:

Resveratrol Sinergie este o formula avansata anti cancer cu fito farmaceutice
trans Resveratrol extr. stand. 20%, 50 mg din (Poligonum cuspidatum), Extract din Samburi de Struguri extr.stand. OPC 95% din: Saminta de Struguri Rosii (Vitis Vinifera), 100 mg, Quercitina extr. stand. 95% 200 mg, Acid Elagic extr. stand. 40% 200 mg, Ceai Verde Supreme extr. stand. EGCG 50%, 200 mg, L-Lizina 250 mg, Vitamina C 250 mg.

Produse naturale din medicina traditionala

Produse naturale din medicina traditionala

Hipertermia efecte terapeutice

Hipertermia efecte terapeutice

- Hipertermia subclinica intre 37°C - 38,5°C cu sprijin terapeutic de vasodilatatie, cresterea circulatiei sanguine,

- Hipertermia moderata intre 38,5°C - 40°C ca stimulator imunitar,

- Hipertermia intermediara intre 40°C - 41,5°C ca sprijin la tratamentele citostatice,

- Hipertermia extrema efectuata de medici specialisti intre 41,5°C - 43°C cu efect de distrugerea celulelor canceroase

2. Relatia timpului de actiune a caldurii si temperatura la tranzitul de 42°C la 43°C este relevanta la hipertermia clinica

Hipertermia mecanismele actiunii energiei si a gradientului temperaturii asupra membranei celulare canceroase si inducerea apoptozei la celulele tumorale

Hipertermia mecanismele actiunii energiei si a gradientului temperaturii

3. Hipertermia un tratament anticancer induce moartea celulara in comparatie cu alti agenti citotoxici - EGCG citostatic natural

4. Hipertermia combinat cu citostatice la cancer de esofag - EGCG citostatic natural

5. Hipertermia o terapie anticancer ca adjuvant la radioterapie pentru metastaza de melanom malign, studiu randomizat trial

6. Radioterapia intensiva inainte de operatie impreuna cu hipertermia locala la tratamentul carcinomului gastric

Hipertermia la distrugerea de celule tumorale

Hipertermia la distrugerea de celule tumorale

Hipertermia world wide web

Hipertermia world wide web

 

Bibliografie-Referinte:
Bibliografie Referinte

 

1. Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson DA, Phillips TL, Gutin PH. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Department of Radiation Oncology, University of California, San Francisco 94143-0226, USA. Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):287-95.
2. Field SB, Morris CC. The relationship between heating time and temperature: its relevance to clinical hyperthermia. Radiother Oncol. 1983 Nov;1(2):179-86.
3. Vidair CA, Dewey WC. Division-associated and division-independent hyperthermic cell death: comparison with other cytotoxic agents. Department of Radiation Oncology, University of California, San Francisco 94143. Int J Hyperthermia. 1991 Jan-Feb;7(1):51-60.
4. Kitamura K, Kuwano H, Watanabe M, Nozoe T, Yasuda M, Sumiyoshi K, Saku M, Sugimachi K. Prospective randomized study of hyperthermia combined with chemoradiotherapy for esophageal carcinoma. Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan. J Surg Oncol. 1995 Sep;60(1):55-8.
5. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Danish Cancer Society Department of Experimental Clinical Oncology, Aarhus. Lancet. 1995 Mar 4;345(8949):540-3.
6. Shchepotin IB, Evans SR, Chorny V, Osinsky S, Buras RR, Maligonov P, Shabahang M, Nauta RJ. Intensive preoperative radiotherapy with local hyperthermia for the treatment of gastric carcinoma. Lombardi Cancer Center, Georgetown University, Washington, DC. Surg Oncol. 1994 Feb;3(1):37-44.

Parerea din pasajele acestui site nu a fost independent cercetate sau confirmate